Bioanalytics – Chemical
The main aim of this lecture will be to introduce the label-free differential mass spectrometry technique as a useful and reproducible quantitative method for global proteomic profiling.
Yates and colleagues are focused on advancing mass spectrometry as an important bioanalytical tool for life sciences research and drug development. In contrast to antibody-based methods that measure one protein at a time, mass spectrometry allows thousands of proteins to be examined together with unprecedented speed and sensitivity. One of their strategies, differential mass spectrometry, couples state-of-the-art, high-resolution Fourier-transform mass spectrometry with cloud-computing image processing tools to identify and quantify proteins that exhibit a statistically significant change in abundance as a function of time, treatment, or condition. This new quantitative proteomics technique creates many avenues for studying the nature and function of proteins in cells, tissue, or clinically accessible bio-fluids. Importantly, mass spectrometry also provides a direct path for translating these discoveries into new assays or diagnostic tests that measure biologically relevant proteins with absolute molecular specificity.
We have applied differential mass spectrometry to the analysis of large longitudinal studies and demonstrated to identify and quantify candidate biomarkers of disease, treatment, and age progression. Here we will describe the application of differential mass spectrometry for the detection of novel drug targets and target engagement markers. We will demonstrate how we have leveraged state of the art analytics and cloud computing to enable detailed and efficient analysis of proteomics data.
In conclusion, label-free differential mass spectrometry is a useful and versatile approach for the identification and quantification of biologically relevant proteins and metabolites in complex clinical samples.